^
Association details:
| Biomarker: | FGF19 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + H3B-6527 (FGFR4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Excerpt:
…these observations suggest that palbociclib combines well with H3B-6527 to enhance H3B-6527 efficacy in FGF19-overexpressing HCC models.
DOI:
10.1158/0008-5472.CAN-17-1865
